A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Start Date21 Mar 2025

Sponsor / Collaborator

Sun Pharmaceutical Industries Ltd.

ChiCTR2400092920

/ Not yet recruitingPhase 4IIT

A multicenter, prospective, observational real-world study evaluating the efficacy and safety of switching biological treatments in patients with moderate to severe plaque psoriasis.

Start Date11 Oct 2024

Sponsor / Collaborator

The Affiliated Suzhou Hospital of Nanjing Medical University

[+1]

NCT06488170

/ Active, not recruitingNot Applicable

Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting - Light Version

The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).

Start Date04 Apr 2024

Sponsor / Collaborator

Almirall SA

100 Clinical Results associated with Tildrakizumab-ASMN

100 Translational Medicine associated with Tildrakizumab-ASMN

100 Patents (Medical) associated with Tildrakizumab-ASMN

343

Literatures (Medical) associated with Tildrakizumab-ASMN

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits

Article

Author: Rivieccio, Antonia ; Campione, Elena ; Bianchi, Luca ; Artosi, Fabio ; Lanna, Caterina ; Cattani, Chiara

BACKGROUND:

Psoriasis is frequently associated with metabolic syndrome and an increased cardiovascular risk. Tildrakizumab, an IL-23 inhibitor, may affect metabolic parameters in addition to improving skin severity.

AIM OF THE STUDY:

To evaluate the impact of increasing tildrakizumab dosage on lipid and glucose levels in psoriasis patients with metabolic syndrome who showed a partial response to the standard 100 mg dose.

MATERIALS AND METHODS:

Twenty-five patients with psoriasis and metabolic syndrome were enrolled in a 52-week prospective study. After 16 weeks of treatment with 100 mg tildrakizumab, patients with an absolute PASI >2 were switched to 200 mg. Total cholesterol, LDL, and glucose were measured at baseline, week 16, week 40, alongside PASI and DLQI.

RESULTS:

At baseline, mean total cholesterol, LDL, and glucose were 190.7, 120.1, and 99.4 mg/dL, respectively. The 100 mg dose did not result in significant metabolic changes at week 16. However, switching to 200 mg tildrakizumab led to significant reductions at week 40 in total cholesterol (178.3 mg/dL), LDL (110.1 mg/dL), and glucose (87.2 mg/dL) (all p < 0.05). Significant improvements in PASI (1.2) and DLQI (0.2) were also observed (p < 0.05).

CONCLUSIONS:

Increasing the tildrakizumab dose to 200 mg in partial responders with metabolic syndrome significantly improved both skin severity and metabolic profiles, lowering cholesterol, LDL, and glucose. These findings suggest a possible dose-dependent effect of tildrakizumab on metabolic parameters through enhanced IL-23 inhibition.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

Review

Author: Ständer, S. ; Thaçi, D.

Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.

01 Sep 2025·Dermatology and Therapy

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis

Article

Author: Yang, Ya-Wen ; Grewal, Parbeer ; Purdy, Kerri ; Oroz, Irina ; Abbarin, Nastaran ; Vender, Ron ; Langley, Richard G ; Papp, Kim A ; Vigelis, Sandra ; Lansang, Perla ; Park-Wyllie, Laura ; Lovegrove, Fiona ; Hooper, Becky ; Disher, Tim

INTRODUCTION:

For some patients with plaque psoriasis (PsO), a rapid response (i.e. short interval to time to onset of action [TOA]) is desired. The primary objective was to determine average time to achieve a Psoriasis Area and Severity Index (PASI) 90 response (50% of patients) for individual biologics or targeted therapies. Secondary outcomes included the average time to achieve a PASI 75 response (50% of patients), as well as PASI 90 and PASI 75 responses over the first 16 weeks of therapy.

METHODS:

A systematic targeted literature review was conducted to identify phase III and IV randomised, double-blinded trials according to pre-specified eligibility criteria that investigated interleukin (IL)-12/23 inhibitors, IL-17 inhibitors, IL-23 inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase (PDE) inhibitors. Using proportions of patients achieving PASI 90 or 75 responses over 16 weeks, network meta-analyses were conducted to estimate response over time. This was presented as curves, and TOA was summarized as median time to reach the 50th percentile.

RESULTS:

Forty-five trials were included in the main analyses. The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks. This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9-10 weeks, and the IL-12/23 inhibitor at 11-12 weeks. Although wide and overlapping credible intervals and similar point estimates were observed, these results suggest onset of action does not vary greatly across biologics in these classes. Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors. Onset of PASI 75 response showed similar trends to PASI 90 response.

CONCLUSIONS:

IL-17 inhibitors, followed by IL-23 inhibitors, have the most rapid TOA among PsO biologics evaluated; any differences in onset of action between specific agents within the same drug class are not statistically or clinically significant. These analyses will allow clinicians to make more informed treatment decisions for their patients.

News (Medical) associated with Tildrakizumab-ASMN

18 Sep 2025

·pharma.economictimes.indiatimes.com

Focusing on specific needs key differentiator for Sun Pharma: Dilip Shanghvi

New Delhi: For India’s largest drug maker Sun Pharma , focusing on specific needs unaddressed by existing therapies stands as a differentiator, said Dilip Shanghvi , its Executive Chairman at an event on quality management that had representations from across industries. Sun Pharma has distinguished itself by sharply focusing on specific areas in contrast to companies that constantly chase newer segments and products. Speaking at the Indian Foundation for Quality Management (IFQM) Symposium over a virtual call, Shanghvi noted when Sun Pharma started operations in India, the market was dominated by large international companies but because of its small size, an agile workforce and by connecting with the customers, the company could identify areas that did not fill the requirement of patients. “We focus on developing drugs which can avoid some of the side effects of the existing products with a better delivery system and fulfill the needs of patients more effectively” he added. “Currently our R&D spend is around $450 million (annually) which is increasing year-on-year and the idea is to develop products that address the unmet challenges patients face with currently available therapies and this helps to differentiate us in the market” Shanghvi said at a panel discussion. Sun Pharma commands a portfolio of therapies that is engineered to target therapeutic domains overlooked by existing treatments and unlocks niche markets that, though modest in scale but have limited competition. Sun Pharma’s innovative drugs portfolio spans dermatology, anti-cancer and ophthalmology drugs. One of the successful products in the company’s specialty business is Ilumya (tildrakizumab-asmn), an interleukin-23 (IL-23) inhibitor which competes against giants such as Johnson and Johnson ’s Stelara (Ustekinumab) which targets two cytokines— IL-12 and IL-23— and both approved for plaque psoriasis by the US FDA . Launched in FY2019, Ilumya recorded net sales of (FY25) $681 million dollar (around ₹5,750 crore). Notably, similar projections have been made for its recently launched Leqselvi , a JAK 1/2 inhibitor indicated for the treatment of severe alopecia areata (a condition that leads to severe hair loss). According to industry experts Leqselvi has a higher dose of 8mg twice daily schedule, which places it in a dominant position against its rival Olumiant of Eli Lilly which is a 2mg and 4mg once-daily pill. During the discussion the industry veteran who founded Sun Pharma in 1983 also noted that, “India accounts for a large patient base, it represents about 2 percent of the global pharmaceutical market so for us as a company to grow it was important to go outside India while we focus on India.” “Today, two-thirds of our total revenue comes from international markets. While it took longer than expected for our US business to generate cash flows, with our continued investments in products tailored for the US market, has delivered very positive results over the years,” he added. Commenting on acquisitions and their integration Shanghvi said, “ Historically we have acquired business which are not very different, and our largest acquisition of Ranbaxy took us very long time but I am quite happy with the change it has brought ” “We recognise that even if, as a company, we haven’t succeeded in some cases that doesn’t mean the strategy is wrong. One simply has to find a better way to execute it,” he stressed. The Indian drugmaker had onboarded Ranbaxy in 2014 from Japanese giant Daiichi Sankyo for a total consideration of around $4billion— $3.2 billion for the acquisition and around $800 million for debt. Before its takeover by Sun Pharma, Ranbaxy was embroiled in charges of fraud and fabrication of data to gain product approvals in the US. It later pleaded guilty of distributing adulterated drugs in the US and was charged a $500 million fine by the US government. By Abhijeet Singh ,

AcquisitionDrug ApprovalBiosimilar

17 Sep 2025

·www.businesswire.com

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology

PARIS--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France. At the congress, Almirall contributes a total of 44 scientific abstracts focused on advancing patient care across the company’s broad portfolio of dermatological treatments including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa. With a strong emphasis on real-world evidence, patient-reported outcomes, and well-being, Almirall’s scientific programme includes multiple presentations, two expert-led symposia on psoriasis and atopic dermatitis, and an interactive exhibition booth supporting dermatologists in their daily practice and effective treatment choices for their patients. “The EADV congress is one of the most important platforms for exchange and learning about scientific and clinical advances in Dermatology. The Almirall team is excited to engage in conversations with leading experts and researchers to advance skin science and to develop meaningful solutions for patients. We are looking forward to discussing our new real-world evidence and clinical data for treatments across our broad portfolio to improve health outcomes for patients and support dermatologists in everyday practice,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer. Atopic Dermatitis: first real-world evidence study and new data on long-term efficacy and well-being of lebrikizumab Almirall presents interim results from the ADlife study, offering – for the first time - real-world evidence on the treatment of atopic dermatitis with lebrikizumab, featuring 100 patients treated for 16 weeks. The ADlife study demonstrates lebrikizumab is highly effective in treating moderate to severe atopic dermatitis with clinically relevant improvements in AD symptoms, already after 4 weeks of treatment, and a consistent safety profile. This data suggests that efficacy seen in randomized clinical trials translates well into the real-world setting - even in a more complex patient population. New data from the long-term extension ADjoin study shows that out of the patients showing significant improvement of their AD symptoms at week 16, those responses remained sustained after two-years of continuous treatment with lebrikizumab, as measured by absolute scores which are considered clinically relevant as they show response regardless of baseline severity. Further supporting its long-term efficacy, improvements in patient reported outcomes, such as itch and sleep (measured by POEM) were also observed up to 3 years of treatment with lebrikizumab. The ADvantage study – the first trial to utilize the WHO-5 Well-being Index in the assessment of an atopic dermatitis treatment – demonstrates the positive impact of lebrikizumab on holistic care for patients with moderate-to-severe atopic dermatitis who often show a significant impairment of their psychological well-being. Treatment with lebrikizumab was associated with improved psychological well-being in adult and adolescent patients to levels similar to a healthy population – already after 16 weeks - and were maintained for up to 52 weeks of treatment. Results from the ADvocate 1 and 2 studies reinforce lebrikizumab’s ability to deliver high rates of both skin clearance and itch relief after 16 weeks of treatment. First results were observed as early as week 4 compared to placebo and were maintained through to 52 weeks after treatment was initiated. Improvements in both the severity of the skin condition and itch translate into meaningful improvements in patient‑reported outcomes in atopic dermatitis1. Almirall’s symposium on atopic dermatitis, “Long-term control in Atopic Dermatitis: Elevating Therapeutic Goals” will be chaired by Prof. Sébastien Barbarot (France), and feature Prof. Tilo Biedermann (Germany), Prof. Richard Warren (UK), and Dr. Alessandra Narcisi (Italy). It will showcase new evidence on the role of IL-13 in AD pathogenesis, supporting the real-world evidence and the long-term efficacy of lebrikizumab delivering meaningful health benefits for patients. “Our symposium will highlight the unmet needs in atopic dermatitis and the pivotal role of IL-13 in disease pathophysiology. Through long-term data from clinical trials, real-world evidence and clinical cases, we’ll discuss how systemic biologic therapies like lebrikizumab are transforming care for patients and healthcare professionals”, commented Prof. Sébastien Barbarot. Psoriasis: advancing disease management and patient outcomes Almirall will present new effectiveness data on tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from the real world ZODIPSO and CzATCH studies. These studies demonstrate high effectiveness of the treatment in high impact areas including nails, scalp, and the genital area. The TIL-SENIOR study explores the needs of elderly patients and how treatment with biologics like tildrakizumab can address these and offer a meaningful therapeutic option, while the TIL-TWO study shows how patients with elevated body weight or high-burden of disease can benefit from treatment with tildrakizumab 200 mg. The PROCARE-t study demonstrates high patient satisfaction with the psoriasis care provided by both hospital pharmacists and dermatologists during the treatment with tildrakizumab. Healthcare Professionals (HPCs) also expressed high satisfaction with the treatment showing the importance of multidisciplinary care in dermatology involving dermatologists and pharmacists. New data from the PRO-SCALP study show that CAL/BPD PAD(TM) cream delivers significant symptom relief of mild-to-moderate psoriasis of the scalp – which is particularly challenging to treat. It also demonstrated the treatment achieving enhanced emotional well-being, and overall improvements in daily life for patients. Almirall will also host a focused symposium on remaining unmet needs in psoriasis, “Psoriasis: Is there anything left to solve?”, Chaired by Prof. Jo Lambert (Belgium), with Dr. Andreas Pinter (Germany) and Dr. Pedro Mendes Bastos (Portugal). R&D pipeline: new insights on the treatment of large areas affected by Actinic Keratosis (AK), and phase I data on novel treatment for Hidradenitis Suppurativa (HS) Almirall will share new data from the TirbAKare study demonstrating tirbanibulin’s suitability for treating large skin areas of up to 100 cm2 affected by actinic keratosis. The results show that tirbanibulin provides statistically significant and clinically meaningful reduction in AK lesion count compared to vehicle at day 57 while offering a favorable safety profile. These results confirm tirbanibulin’s efficacy and tolerability, consistent with previous findings in controlled trials and real-world evidence when treating larger AK areas. Late-breaker: Phase I data on LAD191, a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL-1RAP), in patients affected by Hidradenitis Suppurativa suggest a favorable safety and tolerability profile, along with early signs of clinical improvement supporting the continued development of this asset. Advancing skin science at EADV 2025 Almirall’s booth at EADV (Pavilion 7.2, Booth D06) will offer visitors the opportunity to explore the latest innovations in dermatology and insights into patient needs through interactive educational content and global disease awareness initiatives. Highlights include: the global campaign, “Sanctuary Salon”, which educates about the impact of skin conditions on daily life and self-care, especially in the scalp area, a spotlight on the emotional burden experienced by AD patients, and the possibility for visitors contribute to a psoriasis patient association. About Almirall Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. For more information, please visit https://www.almirall.com/ Legal notice: This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law. ANNEX: 34th EADV Congress presentations and poster details Satellite Symposium on psoriasis: Psoriasis: is there anything left to solve? Chair: Prof. Jo Lambert, Belgium Speakers: Dr. Andreas Pinter, Germany; Dr. Pedro Mendes Bastos, Portugal Thursday 18th September at 17:45 (CEST) / Room S06. Pavilion 7.3. Satellite Symposium on atopic dermatitis: Long-term control in Atopic Dermatitis: Elevating Therapeutic Goals. Chair: Prof. Sébastien Barbarot, France Speakers: Prof. Tilo Biedermann, Germany; Prof. Richard Warren, United Kingdom; Dr. Alessandra Narcisi, Italy. Friday, 19th September at 13:00 (CEST)/ Room S05, Pavilion 7.3. Full abstracts will be available on the EADV 2025 Congress platform from 07:00 CEST on 17 September 2025 – see full list of accepted abstracts below: Ebglyss® (lebrikizumab) Ilumetri® (tildrakizumab) Wynzora® (CAL/BDP) PAD™ Cream Klisyri® (tirbanibulin) and actinic keratosis LAD191 and Hidradenitis Suppurativa 1 Silverberg et al. J Dermatolog Treat 2024; 35(1):2428729.

Clinical ResultPhase 1

23 Jul 2025

·www.echemi.com

Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24

Sun Pharmaceutical Industries Ltd. announced that its leading biologic drug, Ilumya (tildrakizumab-asmn), achieved the primary endpoint in both INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies for active psoriatic arthritis (PsA). At Week 24, patients receiving Ilumya experienced statistically significant improvements over placebo, as measured by the ACR20 response—indicating at least a 20% reduction in tender and swollen joints and other disease indicators. Ilumya, a selective IL-23 inhibitor, blocks key inflammatory pathways in autoimmune conditions. Already approved for moderate-to-severe plaque psoriasis, the drug generated $681 million (₹5,750 crore) in FY25, accounting for 56% of Sun Pharma’s specialty drug revenue. Sun Pharma’s global specialty chief, Marek Honczarenko, highlighted that these results reinforce Ilumya’s potential as a new therapeutic option for PsA. Full trial data will be shared at upcoming medical conferences. Competition is intensifying in the psoriatic arthritis market, with Bristol Myers Squibb’s oral TYK2 inhibitor Sotyktu also meeting ACR20 response in late-stage trials and achieving $246 million in 2024 sales. As both injectable and oral therapies advance, patients could soon benefit from more effective and diverse treatment choices.

Phase 3Clinical ResultDrug Approval

100 Deals associated with Tildrakizumab-ASMN

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tildrakizumab-ASMN	L04AC	DB14004

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Plaque psoriasis	United States	Sun Pharmaceutical Industries Ltd.	20 Mar 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis	Phase 3	United States	Sun Pharmaceutical Industries Ltd.	21 Mar 2025
Psoriasis	Phase 3	Bulgaria	Sun Pharmaceutical Industries Ltd.	21 Mar 2025
Psoriasis	Phase 3	Hungary	Sun Pharmaceutical Industries Ltd.	21 Mar 2025
Psoriasis	Phase 3	Poland	Sun Pharmaceutical Industries Ltd.	21 Mar 2025
Psoriasis of nail	Phase 3	United States	Sun Pharmaceutical Industries Ltd.	13 May 2021
Psoriasis of nail	Phase 3	Australia	Sun Pharmaceutical Industries Ltd.	13 May 2021
Psoriasis of scalp	Phase 3	United States	Sun Pharmaceutical Industries Ltd.	29 Mar 2019
Psoriasis of scalp	Phase 3	Australia	Sun Pharmaceutical Industries Ltd.	29 Mar 2019
Arthritis, Psoriatic	Phase 3	Argentina	Sun Pharmaceutical Industries Ltd.	29 Aug 2018
Arthritis, Psoriatic	Phase 3	Hungary	Sun Pharmaceutical Industries Ltd.	29 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


reSURFACE 1 and reSURFACE 2 (Pubmed \| Br J Dermatol)	Phase 3	Psoriasis	-	Tildrakizumab	gavbltpgax(rjrxuetqzh) = vcykpuvlqp faanmuyrzy (xiotugstwm ) View more	Positive	18 Aug 2025
				Placebo	gavbltpgax(rjrxuetqzh) = xvkldzaoiw faanmuyrzy (xiotugstwm ) View more
NCT04314531 (INSPIRE-2, NEWS) Manual	Phase 3	Arthritis, Psoriatic	385	Ilumya	atqdefrfla(qpzrhkpxlu) = achieved the primary endpoint. rtzxoqsxdz (zfveoaidov ) Met	Positive	23 Jul 2025
				Placebo
NCT04314544 (INSPIRE 1, NEWS) Manual	Phase 3	Arthritis, Psoriatic	385	Ilumya	yxkrllisvx(ewpyvegsxu) = achieved the primary endpoint wfsftsarly (ljzuyijcdi ) Met	Positive	23 Jul 2025
				Placebo
NCT04112810 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Acute Graft Versus Host Disease \| Acute Lymphoblastic Leukemia ... View more	51	Tildrakizumab	ewzejduusz = hvjaeavmoo otcepgpwha (qnjhwlbkcr, tsljvpinmb - lfxpgowntd) View more	-	04 Jul 2025
NCT03897075 (CTgov)	Phase 3	Psoriasis of nail \| Plaque psoriasis	99	placebo (Placebo)	tiukkfjjjx = jmbbqskyzr xfvtplnhur (khjyamfnij, pfhfdxcxee - ouwwbibsdp) View more	-	06 Jun 2025
				Tildrakizumab (Tildrakizumab 100 mg)	tiukkfjjjx = tvwycmsrbc xfvtplnhur (khjyamfnij, admvwvpcru - mietjbsgug) View more
PRNewswire Manual	Phase 3	Plaque psoriasis	99	ILUMYA	pznlvkyskh(pjawlrzznl) = yswbwvibfr fgnlhqkusl (skcsfctghz ) View more	Positive	07 Mar 2025
				Placebo	pznlvkyskh(pjawlrzznl) = iqlgycsomx fgnlhqkusl (skcsfctghz ) View more
NCT03552276 (CTgov)	Phase 2/3	Arthritis, Psoriatic	281	Tildrakizumab (Tildrakizumab 200 mg q4 Weeks)	dbpntgopqc = kmzquntyda leeeoakzvk (tffktddpwb, owefkieops - nnlsrijxsl)	-	21 Nov 2024
				Tildrakizumab (Tildrakizumab 200 mg q12 Weeks)	dbpntgopqc = xkpsoapmic leeeoakzvk (tffktddpwb, yslhzgkqvk - iuxdrflqse)
Pubmed Manual	Not Applicable	Psoriasis	-	Tildrakizumab 200 mg	khrunbwatn(sbcxmvfxyv) = axetebmxls qnqmfkpugc (zphewsxgqw ) View more	Positive	27 Oct 2024
NCT04541329 (CTgov)	Phase 4	inflammatory dermatosis \| Psoriasis vulgaris	7	Tildrakizumab	zrjepizzwn(cragadccmf) = wibvzcovpx apjlukkajh (dcskakehio, 4.1) View more	-	30 Apr 2024
NCT05108766 (Pubmed) Manual	Phase 3	Plaque psoriasis	220	Tildrakizumab 100 mg	cqbhruafjb(kbyihqauwr) = uzfrbuzmtr sxvefgqkqh (hegmjegrcg ) View more	Positive	09 Jan 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis